<DOC>
	<DOC>NCT01234779</DOC>
	<brief_summary>This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg or RO4917838 30 mg or olanzapine 15 mg or placebo orally daily for 4 weeks as inpatients, with a 4-week follow-up period.</brief_summary>
	<brief_title>A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Adult patients, 1865 years of age Diagnosis of schizophrenia (Diagnostic and Statistical Manual of Mental Disorders DSM IVTR) Acute exacerbation which began within the prior 8 weeks Female patients must be surgically sterile or postmenopausal, or agree to use effective contraception for the duration of the study Current psychiatric diagnosis other than schizophrenia Alcohol or substance dependence within 3 months or abuse within 1 month (except for nicotine) Electroconvulsive therapy (ECT) within the prior 6 months Previous treatment with RO4917838 or another GLYT inhibitor Current treatment with olanzapine, or previous treatment with intolerability or lack of response Treatment with longacting injectable antipsychotic within 2 dosing intervals Treatment with &gt; 2 antipsychotics within 3 months History of neuroleptic malignant syndrome Have treatmentresistant schizophrenia as judged by treating physician or have failed two trials according to criteria in protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>